IPM Take
Antimicrobial resistance has had a hierarchy of attention. Bacteria came first. Fungi were too often left in the footnotes.
That neglect has consequences. Patients with serious fungal disease are often diagnosed late, face a thin treatment pipeline and enter systems where laboratory capacity is weakest. WHO’s new blueprint matters because it does not settle for another awareness campaign. It points to the missing machinery: diagnostics, quality-assured antifungals, surveillance, trained staff and regulatory action.
Executive Summary
WHO published its Blueprint for strengthening responses to fungal disease and antifungal resistance. WHO states that fungal diseases affect more than 300 million people each year and remain largely absent from national health plans, global burden estimates, and many antimicrobial-resistance, universal-health-coverage and One Health strategies. The Blueprint sets out implementation guidance across health-system readiness, access to diagnostics and antifungal medicines, laboratory and surveillance capacity, and social and environmental drivers.
Why it matters
- Public authorities: Need fungal disease and antifungal resistance written into AMR plans, not handled as a specialist afterthought.
- Clinicians and laboratories: Need timely diagnostics and treatment pathways, especially for patients at risk of invasive fungal infection.
- Policymakers: Need to understand that fungal disease pressure runs through HIV care, cancer care, transplantation, intensive care and infectious-disease services.
Fungal disease is not a niche problem. It is a political blind spot.
WHO’s Blueprint makes the point plainly: fungal infections carry high mortality, long-term illness and major economic costs, yet are still missing from many strategies meant to protect populations from infectious threats. That omission matters most in low-resource settings, where patients may face delayed diagnosis, limited laboratory capacity and unreliable access to effective antifungal medicines.
The reasons are structural. Fungal diagnostics are often unavailable or too slow. Antifungal stewardship remains weaker than antibiotic stewardship. Surveillance systems may fail to identify resistant fungal pathogens until treatment options are already limited. Meanwhile, resistance is shaped not only by human healthcare, but also by antifungal use in animals, agriculture and the wider environment.
WHO’s response is more practical than rhetorical. The Blueprint identifies four connected areas for action: public-health and health-system readiness; access to therapies, tools and innovation; laboratory systems and surveillance; and social, environmental and One Health drivers. It also identifies 12 catalytic entry points for countries to prioritise investment and implementation.
For IPM, this is the moment to stop treating fungal disease as a specialist issue. Precision infectious-disease care starts with recognising the patient at risk, having a test that can identify the pathogen, and ensuring the right medicine is available when the result arrives.
The science is not the only gap. The delivery system is.
